EMA Authorised: Colobreathe (Colistimethate sodium) — Essential Pharma Limited

View source ↗

Summary

The EMA authorised Colobreathe, a colistimethate sodium inhalation product for cystic fibrosis, with Essential Pharma Limited as the marketing authorisation hol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Colobreathe (Colistimethate sodium)

Snippet

Status: Authorised. Therapeutic area: Cystic Fibrosis. MAH: Essential Pharma Limited. Decision date: 18/12/2024